

Edward Cancer Center

2015 annual report with statistical data from 2014

▶ Introduction

The Edward Cancer Center has made a profound difference in the lives of many cancer patients and their families. Our efforts are far-reaching to provide innovative programming, clinical trials and support groups that educate the community about preventing and treating the disease.

In this annual report, we spotlight achievements and statistical data from 2014. As you'll read, we are many things to many people but more than anything else, we provide hope and promise to fight the battle against cancer.

▶ Edward Cancer Center receives re-accreditation from NAPBC



The Edward Cancer Center received their three year, full accreditation with the National Accreditation Program for Breast Centers (NAPBC).

The Surveyor's remarked, "The Edward Hospital breast program is newly invigorated with the addition of a fellowship trained surgeon to complement the already committed and passionate physicians and staff caring for the breast patients. There is frequent monitoring of the standards and a culture of improvement. The BPL (Breast Program Leadership) challenges itself to quality improvement and finds several projects each year to address. The breast program is growing and expanding."

▶ Psychosocial and Community Outreach

Providing support and education to cancer patients is a key to the success of the Edward Cancer Center. Throughout the year, many community outreach programs were offered to a variety of audiences. The Edward Cancer Center is always trying new ways to increase the community's awareness about the importance of prevention and early detection. This is accomplished through lectures, cooking classes, free screenings, and public awareness programs.

To help cancer patients, the Edward Cancer Center offers support groups for all types of cancers; therapeutic arts and crafts groups; parenting support groups; and a quarterly survivorship group to help patients who are recovering from and surviving cancer. Support groups feature education, complementary therapy and strategies for healthy living. A few of the programs include:

Back on Track

This eight-week exercise class is designed to work with the treatment and management of cancer by enhancing aerobic capacity, muscular strength and flexibility.

American Cancer Society Wig Boutique - Plainfield

Losing your hair is hard; finding a free wig isn't. Brand new wigs are offered at no charge to patients whose insurance does not cover a cranial prosthesis. An American Cancer Society-trained volunteer helps patients choose the "right look" from multiple styles and colors available.

Complementary Therapies: Reiki, CranioSacral, Healing Touch and Massage

These therapies promote balance, relaxation and stress release, and are performed one-on-one by trained practitioners.

Special Events

Hoops For Healing

A long standing tradition during Thanksgiving week is the Hoops for Healing Basketball Tournament. The Edward Cancer Center partnered with the Edward Foundation, Naperville North High School and Oswego High School to raise money to support Camp Hope, a camp for kids whose parent or loved one has cancer. Participants in the tournament had a chance to play and gain an awareness of how their efforts can contribute to the good of the community.

Camp Hope

The Edward Cancer Center offered Camp Hope, two, week-long summer camps for kids ages 6-12 whose parent or loved one is facing cancer. 2014 marked our most successful year, with 40 campers in attendance. Tuition to camp was paid for by donations from the Edward Foundation. Campers participated in traditional summer camp activities and also attended therapeutic sessions including arts and crafts, music therapy/drumming, martial arts, scrapbooking, gardening or yoga. Licensed clinical social workers from the Edward Cancer Center facilitated the sessions and were available throughout each day of camp.

American Cancer Society Sponsorship

The Edward Cancer Center continues to be an active supporter of the American Cancer Society (ACS). Edward had a presence at several ACS Relay for Life events, including South Naperville, North Naperville and Plainfield.

▶ Focus on HIPEC

Cytoreductive surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is an advanced surgical procedure used to treat cancers that have originated or spread to the abdominal cavity, such as appendiceal cancer, pseudomyxoma peritonei, colon cancer, gastric cancer, ovarian cancer, peritoneal mesothelioma and sarcoma. HIPEC is accepted as a standard treatment by surgical oncologists from around the world.

George Salti, MD, FACS, one of the nation's most experienced surgical oncologists performing HIPEC, joined our program in 2013 bringing this innovative procedure to our area. Edward Hospital is one of only a few health care providers in the U.S. offering HIPEC treatment.

There are three requirements for a patient to be a candidate for HIPEC according to Dr. Salti: the patient must be healthy enough to withstand the rather long procedure, the cancer must be confined to the abdominal cavity, and all their tumors must be surgically removable.

The first part of the procedure is cytoreductive surgery removing peritoneal surface malignancy to the cellular level of residual disease. The second part of the procedure is Hyperthermic Intraperitoneal Chemotherapy (HIPEC). With HIPEC, the abdominal cavity is bathed with a heated chemotherapy solution for 90 minutes to attack any remaining cancer cells. The higher temperature allows the chemotherapy to get into the cells more easily and makes it harder for the cancer cells to defend themselves from the action of the drug. Using HIPEC limits the area being exposed to the drugs and most of the drug flows out of the body right away allowing higher concentrations of the drug to be used without the possible side-effects of traditional chemotherapy.

HIPEC is a closed system, meaning the solution is never open to the air. Between three and four liters (a little more than 3-4 quarts) of the solution containing the drug is warmed then pumped through a tube into the abdominal cavity at a rate of approximately 1 liter per minute. It exits the cavity through another tube and recirculates through the pump and cavity for 90 minutes. Body temperature will be maintained using cooling blankets and/or ice packs as needed and blood pressure in both the veins and arteries will be monitored.

The first year Dr. Salti came to Edward, he performed 13 HIPEC procedures. That number doubled in 2014 to 26 patients and we are looking at a larger increase in this procedure in 2015.

In 2014 Dr. Salti led 43 Gastrointestinal Tumor Conferences, discussing over 200 new patients with a multidisciplinary team that includes Surgical Oncology, Medical Oncology, Radiation Oncology, Gastrointestinal specialists, Radiology, and Pathology physicians to determine the best diagnosis, treatment and follow up procedures for each patient. Many of these included the discussion of HIPEC to determine if the patient would benefit from this treatment. It is a true group effort, putting the patient's need first.

Focus on HIPEC (*continued*)

We also have a clinical trial for our HIPEC patients: HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry (NCT02082886) which will help provide answers to questions such as how well it is tolerated in different populations or how effective it is in treating specific types of disease. There were 49 patients were enrolled as of December 31, 2014.

▶ Cancer Registry


The Cancer Registry at Edward Hospital of Edward-Elmhurst Health Services (EEHS) is a clinical data management system that collects and analyzes all reportable cancers diagnosed and/or treated at Edward Hospital. The database, which includes demographics, diagnosis, state, treatment and survival outcome, is used for research and quality improvement analysis and has a total of 25,134 cases since its inception on January 1, 1982. The Cancer Registry plays an important role in the cancer program by providing data and documentation of the program's activities in order to achieve accreditation as a Comprehensive Community Cancer Program by the American College of Surgeons (ACoS) Commission on Cancer (CoC). The Cancer Registry also provides all data for accreditation by the National Accreditation Program for Breast Centers (NAPBC).

The Cancer Registry is staffed by two full-time and one part-time Certified Tumor Registrars (CTR) as well as one part-time non-CTR. During 2014, the Cancer Registry activities and achievements included the following:

- Accessioned 1,847 cases of which 1,717 were analytic (diagnosed and/or treated at Edward).
- Maintained a 92% follow-up rate since our reference year of 2004, which exceeds the requirement set forth by ACoS.
- Submitted registry data to ACoS, the American Cancer Society, the Illinois State Cancer Registry (ISCR), and the National Cancer Database (NCDB).
- Participated in data collection for the Chicago Breast Cancer Quality Consortium.
- Coordinated weekly Tumor Board and Breast Cancer Conferences.
- Coordinated Cancer Committee meetings quarterly.
- Participated in the successful 3-year re-accreditation by the NAPBC as a nationally recognized certified Breast Center.
- Coordinated Breast Program Leadership meetings quarterly.
- Provided data for various quality improvement projects.

Edward Cancer Center has 4 weekly Multidisciplinary Tumor Conferences and 1 bi-weekly Conference. The Cancer Registry monitors and tracks the activity at each conference.

▶ 2014 Cancer Conference New Cases



The goal of the Cancer Registry is to continue to be the cornerstone of the cancer program at Edward Health Services by providing valuable data to physicians, nurses, administration, and the community it serves.

Judy Babyar, RHIT, CTR
Lead Cancer Registrar

▶ Oncology Conferences

February 26, 2014
Gastrointestinal Oncology Symposium
Multiple Speakers

October 15, 2014
Neuro-Oncology 2014 Fall Symposium
Multiple Speakers


Summary by Body System and Sex Report

Primary Site	Total %	Male %	Female %
ORAL CAVITY & PHARYNX	26 1.5%	21 3.0%	5 0.5%
Tongue	5 0.3%	5 0.7%	0 0.0%
Salivary Glands	5 0.3%	2 0.3%	3 0.3%
Floor of Mouth	1 0.1%	1 0.1%	0 0.0%
Nasopharynx	1 0.1%	0 0.0%	1 0.1%
Tonsil	12 0.7%	12 1.7%	0 0.0%
Oropharynx	1 0.1%	0 0.0%	1 0.1%
Hypopharynx	1 0.1%	1 0.1%	0 0.0%
DIGESTIVE SYSTEM	294 17.1%	165 23.3%	129 12.8%
Esophagus	17 1.0%	13 1.8%	4 0.4%
Stomach	21 1.2%	14 2.0%	7 0.7%
Small Intestine	13 0.8%	4 0.6%	9 0.9%
Colon Excluding Rectum	91 5.3%	48 6.8%	43 4.3%
Cecum	25	11	14
Appendix	9	5	4
Ascending Colon	17	10	7
Hepatic Flexure	5	3	2
Transverse Colon	9	5	4
Splenic Flexure	2	2	0
Descending Colon	3	2	1
Sigmoid Colon	14	8	6
Large Intestine, NOS	7	2	5
Rectum & Rectosigmoid	51 3.0%	34 4.8%	17 1.7%
Rectosigmoid Junction	11	7	4
Rectum	40	27	13
Anus, Anal Canal & Anorectum	7 0.4%	2 0.3%	5 0.5%
Liver & Intrahepatic Bile Duct	14 0.8%	8 1.1%	6 0.6%
Liver	10	7	3
Intrahepatic Bile Duct	4	1	3
Gallbladder	2 0.1%	0 0.0%	2 0.2%
Other Biliary	10 0.6%	4 0.6%	6 0.6%
Pancreas	62 3.6%	36 5.1%	26 2.6%
Retroperitoneum	3 0.2%	2 0.3%	1 0.1%
Peritoneum, Omentum & Mesent	2 0.1%	0 0.0%	2 0.2%
Other Digestive Organs	1 0.1%	0 0.0%	1 0.1%
RESPIRATORY SYSTEM	160 9.3%	81 11.5%	79 7.8%
Nose, Nasal Cavity & Middle Ear	2 0.1%	1 0.1%	1 0.1%
Larynx	11 0.6%	10 1.4%	1 0.1%
Lung & Bronchus	147 8.6%	70 9.9%	77 7.6%
BONES & JOINTS	2 0.1%	2 0.3%	0 0.0%
Bones & Joints	2 0.1%	2 0.3%	0 0.0%
SOFT TISSUE	18 1.0%	13 1.8%	5 0.5%
Soft Tissue (including Heart)	18 1.0%	13 1.8%	5 0.5%
SKIN EXCLUDING BASAL & SQU	36 2.1%	20 2.8%	16 1.6%
Melanoma -- Skin	33 1.9%	19 2.7%	14 1.4%
Other Non-Epithelial Skin	3 0.2%	1 0.1%	2 0.2%
BREAST	421 24.5%	5 0.7%	416 41.2%
Breast	421 24.5%	5 0.7%	416 41.2%
FEMALE GENITAL SYSTEM	87 5.1%	0 0.0%	87 8.6%
Cervix Uteri	8 0.5%	0 0.0%	8 0.8%
Corpus & Uterus, NOS	51 3.0%	0 0.0%	51 5.0%
Corpus Uteri	50	0	50
Uterus, NOS	1	0	1

Summary by Body System and Sex Report (continued)

Primary Site	Total %	Male %	Female %
Ovary	23 1.3%	0 0.0%	23 2.3%
Vulva	4 0.2%	0 0.0%	4 0.4%
Other Female Genital Organs	1 0.1%	0 0.0%	1 0.1%
MALE GENITAL SYSTEM	131 7.6%	131 18.5%	0 0.0%
Prostate	121 7.0%	121 17.1%	0 0.0%
Testis	9 0.5%	9 1.3%	0 0.0%
Penis	1 0.1%	1 0.1%	0 0.0%
URINARY SYSTEM	163 9.5%	119 16.8%	44 4.4%
Urinary Bladder	70 4.1%	53 7.5%	17 1.7%
Kidney & Renal Pelvis	86 5.0%	60 8.5%	26 2.6%
Ureter	6 0.3%	6 0.8%	0 0.0%
Other Urinary Organs	1 0.1%	0 0.0%	1 0.1%
BRAIN & OTHER NERVOUS SYS	44 2.6%	16 2.3%	28 2.8%
Brain	10 0.6%	7 1.0%	3 0.3%
Cranial Nerves Other Nervous Sy	34 2.0%	9 1.3%	25 2.5%
ENDOCRINE SYSTEM	161 9.4%	49 6.9%	112 11.1%
Thyroid	149 8.7%	41 5.8%	108 10.7%
Other Endocrine including Thymu	12 0.7%	8 1.1%	4 0.4%
LYMPHOMA	82 4.8%	44 6.2%	38 3.8%
Hodgkin Lymphoma	11 0.6%	6 0.8%	5 0.5%
Non-Hodgkin Lymphoma	71 4.1%	38 5.4%	33 3.3%
NHL - Nodal	52	28	24
NHL - Extranodal	19	10	9
MYELOMA	13 0.8%	5 0.7%	8 0.8%
Myeloma	13 0.8%	5 0.7%	8 0.8%
LEUKEMIA	26 1.5%	12 1.7%	14 1.4%
Lymphocytic Leukemia	7 0.4%	3 0.4%	4 0.4%
Acute Lymphocytic Leukemia	2	1	1
Chronic Lymphocytic Leukemia	4	1	3
Other Lymphocytic Leukemia	1	1	0
Myeloid & Monocytic Leukemia	17 1.0%	8 1.1%	9 0.9%
Acute Myeloid Leukemia	8	5	3
Chronic Myeloid Leukemia	8	3	5
Other Myeloid/Monocytic Leuken	1	0	1
Other Leukemia	2 0.1%	1 0.1%	1 0.1%
MESOTHELIOMA	7 0.4%	6 0.8%	1 0.1%
Mesothelioma	7 0.4%	6 0.8%	1 0.1%
MISCELLANEOUS	46 2.7%	18 2.5%	28 2.8%
Miscellaneous	46 2.7%	18 2.5%	28 2.8%
Total	1,717	707	1,010
Exclusions: Not Male and Not Female			0


► **Summary by Body System and Sex Report (continued)**



Images reprinted by the permission of the American Cancer Society, Inc. from www.cancer.org. All rights reserved.


2014 Stage at Diagnosis -Summary by Body

Chart displays AJCC Stage for the 1717 analytic cancer cases first seen at Edward Hospital in 2014.




Top 5 Primary Cancer Sites for 2014

The top 5 primary cancer sites diagnosed and/or treated in 2014 at Edward Hospital which accounts for 979 or 57% of the 1717 analytic cases.



Annual Cancer Cases 2010 - 2014, Edward Hospital





Summary by Body System, Sex, Class, Status and Best AJCC Stage Report

Primary Site	Total (%)	Sex		Class of		Status		Stage Distribution - Analytic Cases Only							Unk	Blank/Inv
		M	F	Analy	NA	Alive	Exp	Stg 0	Stg I	Stg II	Stg III	Stg IV	#8			
ORAL CAVITY & PHARYNX	31 (1.7%)	24	7	26	5	27	4	0	1	4	5	16	0	0	0	
Tongue	6 (0.3%)	5	1	5	1	6	0	0	0	0	2	3	0	0	0	
Salivary Glands	6 (0.3%)	3	3	5	1	5	1	0	1	1	1	2	0	0	0	
Floor of Mouth	2 (0.1%)	2	0	1	1	0	2	0	0	0	0	1	0	0	0	
Nasopharynx	1 (0.1%)	0	1	1	0	1	0	0	0	0	1	0	0	0	0	
Tonsil	13 (0.7%)	13	0	12	1	12	1	0	0	1	1	10	0	0	0	
Oropharynx	1 (0.1%)	0	1	1	0	1	0	0	0	1	0	0	0	0	0	
Hypopharynx	2 (0.1%)	1	1	1	1	2	0	0	0	1	0	0	0	0	0	
DIGESTIVE SYSTEM	323 (17.5%)	181	142	294	29	226	97	23	63	53	71	77	5	1	1	
Esophagus	19 (1.0%)	15	4	17	2	15	4	1	4	0	9	3	0	0	0	
Stomach	24 (1.3%)	16	8	21	3	14	10	0	7	2	3	9	0	0	0	
Small Intestine	14 (0.8%)	5	9	13	1	9	5	1	1	0	9	2	0	0	0	
Colon Excluding Rectum	106 (5.7%)	55	51	91	15	81	25	10	22	20	19	17	2	1	0	
Cecum	26	12	14	25	1	22	4	3	4	6	8	4	0	0	0	
Appendix	11	6	5	9	2	9	2	0	2	4	0	2	0	1	0	
Ascending Colon	20	12	8	17	3	17	3	3	3	5	4	2	0	0	0	
Hepatic Flexure	5	3	2	5	0	4	1	1	3	0	1	0	0	0	0	
Transverse Colon	9	5	4	9	0	6	3	0	4	2	2	1	0	0	0	
Splenic Flexure	2	2	0	2	0	2	0	0	0	0	1	1	0	0	0	
Descending Colon	3	2	1	3	0	2	1	0	2	0	0	1	0	0	0	
Sigmoid Colon	18	10	8	14	4	14	4	3	4	2	3	2	0	0	0	
Large Intestine, NOS	12	3	9	7	5	5	7	0	0	1	0	4	2	0	0	
Rectum & Rectosigmoid	56 (3.0%)	37	19	51	5	53	3	10	12	7	18	4	0	0	0	
Rectosigmoid Junction	11	7	4	11	0	10	1	2	3	2	2	2	0	0	0	
Rectum	45	30	15	40	5	43	2	8	9	5	16	2	0	0	0	
Anus, Anal Canal & Anorectum	7 (0.4%)	2	5	7	0	6	1	1	2	2	1	1	0	0	0	
Liver & Intrahepatic Bile Duct	14 (0.8%)	8	6	14	0	5	9	0	2	2	1	9	0	0	0	
Liver	10	7	3	10	0	3	7	0	2	2	1	5	0	0	0	
Intrahepatic Bile Duct	4	1	3	4	0	2	2	0	0	0	0	4	0	0	0	
Gallbladder	2 (0.1%)	0	2	2	0	0	2	0	0	0	1	1	0	0	0	
Other Biliary	10 (0.5%)	4	6	10	0	7	3	0	0	1	4	2	2	0	1	
Pancreas	63 (3.4%)	36	27	62	1	30	33	0	12	18	4	28	0	0	0	
Retroperitoneum	5 (0.3%)	3	2	3	2	4	1	0	1	1	1	0	0	0	0	
Peritoneum, Omentum & Mes	2 (0.1%)	0	2	2	0	2	0	0	0	0	1	1	0	0	0	
Other Digestive Organs	1 (0.1%)	0	1	1	0	0	1	0	0	0	0	0	1	0	0	
RESPIRATORY SYSTEM	184 (10.0%)	93	91	160	24	106	78	3	41	10	26	79	1	0	0	
Nose, Nasal Cavity & Middle	3 (0.2%)	1	2	2	1	2	1	0	0	1	0	0	1	0	0	
Larynx	12 (0.6%)	10	2	11	1	11	1	2	5	1	1	2	0	0	0	
Lung & Bronchus	169 (9.1%)	82	87	147	22	93	76	1	36	8	25	77	0	0	0	
BONES & JOINTS	4 (0.2%)	3	1	2	2	2	2	0	1	0	0	0	0	1	0	
Bones & Joints	4 (0.2%)	3	1	2	2	2	2	0	1	0	0	0	0	1	0	
SOFT TISSUE	23 (1.2%)	14	9	18	5	17	6	0	6	5	4	2	0	1	0	
Soft Tissue (including Heart)	23 (1.2%)	14	9	18	5	17	6	0	6	5	4	2	0	1	0	
SKIN EXCLUDING BASAL & SQUAMOUS CELL CARCINOMA	144 (2.4%)	28	16	36	8	37	7	7	18	5	4	2	0	0	0	
Melanoma - Skin	40 (2.2%)	26	14	33	7	33	7	7	17	4	3	2	0	0	0	
Other Non-Epithelial Skin	4 (0.2%)	2	2	3	1	4	0	0	1	1	1	0	0	0	0	
BREAST	436 (23.6%)	5	431	421	15	421	15	116	168	91	28	16	0	2	0	
Breast	436 (23.6%)	5	431	421	15	421	15	116	168	91	28	16	0	2	0	
FEMALE GENITAL SYSTEM	91 (4.9%)	0	91	87	4	81	10	1	43	4	25	11	0	3	0	
Cervix Uteri	8 (0.4%)	0	8	8	0	8	0	0	3	0	0	5	0	0	0	
Corpus & Uterus, NOS	52 (2.8%)	0	52	51	1	47	5	1	36	3	6	3	0	2	0	
Corpus Uteri	51	0	51	50	1	47	4	1	35	3	6	3	0	2	0	
Uterus, NOS	1	0	1	1	0	0	1	0	1	0	0	0	0	0	0	
Ovary	26 (1.4%)	0	26	23	3	21	5	0	2	1	16	3	0	1	0	
Vulva	4 (0.2%)	0	4	4	0	4	0	0	2	0	2	0	0	0	0	
Other Female Genital Organs	1 (0.1%)	0	1	1	0	1	0	0	0	0	1	0	0	0	0	
MALE GENITAL SYSTEM	144 (7.8%)	144	0	131	13	138	6	0	16	81	22	12	0	0	0	
Prostate	133 (7.2%)	133	0	121	12	129	4	0	11	79	20	11	0	0	0	
Testis	10 (0.5%)	10	0	9	1	9	1	0	5	2	2	0	0	0	0	
Penis	1 (0.1%)	1	0	1	0	0	1	0	0	0	0	1	0	0	0	
URINARY SYSTEM	170 (9.2%)	124	46	163	7	155	15	44	63	17	21	18	0	0	0	
Urinary Bladder	74 (4.0%)	56	18	70	4	65	9	42	10	7	5	6	0	0	0	
Kidney & Renal Pelvis	89 (4.8%)	62	27	86	3	83	6	1	49	9	15	12	0	0	0	
Ureter	6 (0.3%)	6	0	6	0	6	0	1	4	1	0	0	0	0	0	
Other Urinary Organs	1 (0.1%)	0	1	1	0	1	0	0	0	0	1	0	0	0	0	
EYE & ORBIT	2 (0.1%)	2	0	0	2	1	1	0	0	0	0	0	0	0	0	
Eye & Orbit	2 (0.1%)	2	0	0	2	1	1	0	0	0	0	0	0	0	0	
BRAIN & OTHER NERVOUS SYSTEM	49 (2.7%)	19	30	44	5	41	8	0	0	0	0	0	44	0	0	
Brain	14 (0.8%)	10	4	10	4	7	7	0	0	0	0	0	10	0	0	
Cranial Nerves Other Nervous System	35 (1.9%)	9	26	34	1	34	1	0	0	0	0	0	34	0	0	
ENDOCRINE SYSTEM	162 (8.8%)	49	113	161	1	161	1	0	116	11	16	3	12	1	2	
Thyroid	149 (8.1%)	41	108	149	0	149	0	0	116	11	16	3	0	1	2	
Other Endocrine including Thymus	13 (0.7%)	8	5	12	1	12	1	0	0	0	0	0	12	0	0	
LYMPHOMA	87 (4.7%)	47	40	82	5	72	15	0	19	17	16	29	1	0	0	
Hodgkin Lymphoma	12 (0.6%)	7	5	11	1	11	1	0	4	4	1	2	0	0	0	
Non-Hodgkin Lymphoma	75 (4.1%)	40	35	71	4	61	14	0	15	13	15	27	1	0	0	
NHL - Nodal	55	29	26	52	3	46	9	0	4	11	15	22	0	0	0	
NHL - Extranodal	20	11	9	19	1	15	5	0	11	2	0	5	1	0	0	
MYELOMA	14 (0.8%)	6	8	13	1	13	1	0	0	0	0	0	13	0	0	
Myeloma	14 (0.8%)	6	8	13	1	13	1	0	0	0	0	0	13	0	0	
LEUKEMIA	27 (1.5%)	12	15	26	1	19	8	0	0	0	0	0	26	0	0	
Lymphocytic Leukemia	7 (0.4%)	3	4	7	0	5	2	0	0	0	0	0	7	0	0	
Acute Lymphocytic Leukemia	2	1	1	2	0	1	1	0	0	0	0	0	2	0	0	
Chronic Lymphocytic Leukemia	4	1	3	4	0	4	0	0	0	0	0	0	4	0	0	
Other Lymphocytic Leukemia	1	0	1	1	0	0	1	0	0	0	0	0	1	0	0	
Myeloid & Monocytic Leukemia	18 (1.0%)	8	10	17	1	14	4	0	0	0	0	0	17	0	0	
Acute Myeloid Leukemia	9	5	4	8	1	7	2	0	0	0	0	0	8	0	0	
Chronic Myeloid Leukemia	8	3	5	8	0	7	1	0	0	0	0	0	8	0	0	
Other Myeloid/Monocytic Leukemia	1	0	1	1	0	0	1	0	0	0	0	0	1	0	0	
Other Leukemia	2 (0.1%)	1	1	2	0	0	2	0	0	0	0	0	2	0	0	
MESOTHELIOMA	8 (0.4%)	7	1	7	1	2	6	0	0	0	1	5	0	1	0	
Mesothelioma	8 (0.4%)	7	1	7	1	2	6	0	0	0	1	5	0	1	0	
MISCELLANEOUS	48 (2.6%)	19	29	46	2	26	22	0	0	0	0	0	44	0	2	
Miscellaneous	48 (2.6%)	19	29	46	2	26	22	0	0	0	0	0	44	0	2	
Total	1,847	777	1,070	1,717	130	1,545	302	194	555	298	239	270	146	10	5	
Exclusion Not Male and Not Female														0		

▶ 2014 Edward Cancer Committe Members

Rameez Alasadi, MD
Gastroenterology

Judith Babyar, RHIT, CTR
Cancer Registrar

Paul Backas, MD
Diagnostic Radiology

F. B. Barhamand, M.D.
Hematology/Oncology

Linda Conlin, LCSW
Social Services, Cancer Center

Anne Donnelly, MD
Family Practice

Kathleen Evans, PhD
Pharmacy

Jackie Ford, RN
Manager Inpatient Oncology Unit

Sue Garrard, RTT, BS
Manager Radiation Oncology

Cathy Goldberg, MD
Pathology

Alexander Hantel, MD
Hematology/Oncology
Medical Director

Elizabeth Harvey, MD
Surgery

Joseph Kash, MD
Cancer Liaison Physician
Hematology/Oncology

Vasudha Lingareddy, MD, FACRO
Radiation Oncology

Karen Pekelder, CTR
Cancer Registrar

Amy Phalen, RN, BSN, OCN, CBCN
Clinical Educator/Quality Coordinator

Kimberly Rohan, RN, CNS, ACON
Advanced Practice Nurse

George Salti, MD
Surgical Oncology

Yousuf Sayeed, MD
Anesthesiology

Kathy Seymour, RN, BSN, OCN, CCRP
Clinical Research

Samir Undevia, MD
Chairman, Cancer Committee
Hematology/Oncology

Jenna VanGilder, RN, BSN, OCN
Director, Cancer Services

Elyse Weber, MS, CGC
Genetic Counselor

Jill Wozny, RN, BSN, OCN
Breast Program Navigator

Alternates:

Mansoina Baweja, MD
Hematology/Oncology

Anita Brown, RN
Research

Sue Budds, RN
Oncology APN

Sharon Kelleher, LCSW
Social Services, Cancer Center

Mohammed Khan, MD
Anesthesiology

Oh-Hoon Kwon, MD
Radiation Oncology

Barbara Merek, RN
Oncology

Dwight Morrow, MD
Pathology

Peter Petratos, MD
Surgery

Maria Quejada, MD
Hematology/Oncology